2013 annual shareholder meeting dwight babcock, ceo
DESCRIPTION
2013 Annual Shareholder Meeting Dwight Babcock, CEO. Innovative Solutions Begins With A Great Team. Fred Swindler Bill Cavanagh Brien Ragle Krista Cline Dale Boyce Clay O’Laughlin. State of Prostate Cancer Treatments. Brachytherapy External Beam Robotic Surgery - PowerPoint PPT PresentationTRANSCRIPT
2013 Annual Shareholder Meeting
Dwight Babcock, CEO
Fred Swindler Bill Cavanagh
Brien Ragle Krista Cline
Dale Boyce Clay O’Laughlin
Brachytherapy
External Beam
Robotic Surgery
Proton Beam
Task Force Report
Gliobastoma Brain Cancer Metastatic Brain Cancer Meningioma Brain Tumors Head and Neck Cancer Non Small Cell Lung Cancer Gynecologic Cancer
Prostate – Consolidation of I-125 & P-103 Brain Cancers and Tumors – None GliaSite Balloon Radiation Therapy – None Lung Cancer – I-125 sutured seeds No Mesh Gynecologic Cancer - None
*Published Papers Are Needed Prior To General Adoption
Pharma Model
Product development and pre-human testing: 5 years
Human Clinical Trials: 5 years
FDA Approval: 2 years
Adoption
IsoRay Prostate ModelProduct development 510(k) FDA Approval 1-2 years
Early Adopters DataPublished Papers
5-6 years
Wider Scale Adoption
IsoRay New Product ModelProduct development 510(k) FDA Approval
1-2 years
Early Adopters DataPublished Papers
1-3 years
Wider Scale Adoption
Cornell Weill – Lung Cancer Cornell Weill – Metastatic Brain Cancer Archibold Medical – Lung Cancer MD Anderson – Intermediate Prostate
Cancer Sylvestor – Dual Therapy Prostate Cancer Cole – Mono Therapy Prostate Cancer Barrows – Meningioma Brain Tumors